Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pediococcus acidilactici CECT9879
- Development stage
- Preclinical
- Lead developer
- Genbioma Aplicaciones
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pediococcus acidilactici CECT9879, also known by the code name pA1c, is a probiotic bacterial strain (and its heat-inactivated postbiotic form pA1c®HI) developed for the management of metabolic diseases such as type 2 diabetes, obesity, and metabolic syndrome. The strain works by modulating the gut microbiota—specifically increasing the abundance of Akkermansia muciniphila and reducing Prevotella—and regulating the insulin/IGF-1 signaling pathway. In preclinical models, it has demonstrated the ability to improve glucose tolerance, reduce visceral adiposity, and decrease the expression of proinflammatory cytokines like monocyte chemotactic protein-1 (MCP-1). It also enhances the expression of glucose transporters GLUT-1 and GLUT-4. The postbiotic form retains metabolic efficacy even after high-heat processing, making it suitable for incorporation into functional foods.
- Brand names
- pA1cpA-1cpA 1cpA1c®HI
- Other names
- Pediococcus acidilactici CECT 9879
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)GLUT1 (Glucose transporter 1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on Pediococcus acidilactici CECT9879.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pediococcus acidilactici CECT9879.